CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $969,122 | -17.7% | 21,351 | +1.7% | 0.01% | -20.0% |
| Q2 2023 | $1,178,154 | +20.9% | 20,986 | -2.6% | 0.01% | +11.1% |
| Q1 2023 | $974,752 | +14.7% | 21,551 | +3.1% | 0.01% | +12.5% |
| Q4 2022 | $850,032 | -35.0% | 20,911 | +4.6% | 0.01% | -42.9% |
| Q3 2022 | $1,307,000 | +8.2% | 19,996 | +0.6% | 0.01% | +16.7% |
| Q2 2022 | $1,208,000 | +16.3% | 19,876 | +20.1% | 0.01% | +50.0% |
| Q1 2022 | $1,039,000 | -16.4% | 16,549 | +0.9% | 0.01% | -11.1% |
| Q4 2021 | $1,243,000 | -32.7% | 16,407 | -0.6% | 0.01% | -40.0% |
| Q3 2021 | $1,848,000 | -30.4% | 16,511 | +0.7% | 0.02% | -31.8% |
| Q2 2021 | $2,655,000 | +26.6% | 16,403 | -4.7% | 0.02% | +22.2% |
| Q1 2021 | $2,097,000 | -10.3% | 17,213 | +12.8% | 0.02% | -14.3% |
| Q4 2020 | $2,337,000 | +80.6% | 15,262 | -1.4% | 0.02% | +61.5% |
| Q3 2020 | $1,294,000 | +97.3% | 15,476 | +73.4% | 0.01% | +44.4% |
| Q2 2020 | $656,000 | +119.4% | 8,927 | +26.6% | 0.01% | +80.0% |
| Q1 2020 | $299,000 | – | 7,052 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |